|
|
We are currently recruiting for the following treatment trials:
| Study Title: |
A prospective, randomized, multi-center, double-blind, 26-week, placebo-controlled trial of memantine (10mg BID) for the frontal and temporal subtypes of frontotemporal dementia |
| Principal Investigator: |
Murray Grossman, MD |
| Sponsor: |
Forest Research Institute |
| Conditions Studied: |
Frontotemporal Dementia, Semantic Dementia |
| Intervention: |
10 mg of memantine or placebo taken twice-daily |
| Purpose: |
The study is designed to determine whether memantine is effective in slowing the rate of behavioral decline in frontotemporal dementia. The study will also assess the safety and tolerability of long-term treatment with memantine in patients with frontotemporal dementia (FTD) or semantic dementia (SD) and lastly, whether memantine is effective in slowing the rate of cognitive decline in frontotemporal dementia. |
| What is involved? |
|
Six visits and 2 phone calls over a period of 8 months, with visits more frequent at the beginning of the study. |
|
Neurological and physical examinations, cognitive testing and neuropsychiatric assessments, EKGs, blood and urine specimen collection, and vital signs. |
|
| Contact Info: |
Lauren M. Massimo, MSN, CRNP
Clinical Research Coordinator
3400 Spruce Street
Department of Neurology
3 West Gates Building
Philadelphia, PA 19104-4283
Office: 215-349-5725 |
|
|
